A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer
Status:
Withdrawn
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this research study is to see whether adding bavituximab (an
investigational drug) to the standard chemotherapy drug taxane, will improve the results of
the treatment for early- stage Triple Negative Breast Cancer followed by Standard- of- Care
surgery